A large‐scale, multicenter characterization of BRAF G469V/A‐mutant non‐small cell lung cancer

Documenti analoghi

• Optimum timing of lung resection surgery following SARS‐CoV‐2 infection for non‐small cell lung cancer
  di: Yanbo Yang, et al.
  Pubblicazione: (2024)
• Treatment preferences among Japanese patients and physicians for epidermal growth factor receptor‐mutant non‐small cell lung cancer
  di: Akito Hata, et al.
  Pubblicazione: (2024)
• Schizandrin A induces non‐small cell lung cancer apoptosis by suppressing the epidermal growth factor receptor activation
  di: Linhai Zhu, et al.
  Pubblicazione: (2024)
• Survival and safety analysis of COVID‐19 vaccine in Chinese patients with non‐small cell lung cancer
  di: Wei Xu, et al.
  Pubblicazione: (2024)
• A multicenter, real‐world study on effectiveness and safety of first‐line modified PD‐1 inhibitors with chemotherapy in advanced non‐small cell lung cancer (aNSCLC) with drive gene‐negative
  di: Tao Li, et al.
  Pubblicazione: (2024)